US Patent

US9592208 — Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol

Method of Use · Assigned to Novartis AG · Expires 2032-03-30 · 6y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a solid oral pharmaceutical composition containing a S1P receptor modulator, a filler, and a cyclodextrin.

USPTO Abstract

A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor modulator; (b) a filler, and (c) a cyclodextrin.

Drugs covered by this patent

fingolimod-hydrochloride (FINGOLIMOD HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2315`	—	fingolimod-hydrochloride

Patent Metadata

Patent number: US9592208
Jurisdiction: US
Classification: Method of Use
Expires: 2032-03-30
Drug substance claim: No
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.